Davenport & Co’s Protalix BioTherapeutics PLX Stock Holding History

Davenport & Co’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,000	Closed	-$23K	–	1031
2022 Q3	$23K	Hold	22,000	–	–	﹤0.01%	981
2022 Q2	$24K	Buy	22,000 +10,000	+83%	+$11.7K	﹤0.01%	982
2022 Q1	$13K	Hold	12,000	–	–	﹤0.01%	1058
2021 Q4	$10K	Sell	12,000 -24,000	-67%	-$25.1K	﹤0.01%	1076
2021 Q3	$48K	Buy	36,000 +24,000	+200%	+$36.5K	﹤0.01%	1017
2021 Q2	$23K	Hold	12,000	–	–	﹤0.01%	941
2021 Q1	$54K	Buy	+12,000	New	+$55.9K	﹤0.01%	790
2019 Q4	–	Sell	-2,000	Closed	-$9K	–	749
2019 Q3	$9K	Hold	2,000	–	–	﹤0.01%	679
2019 Q2	$9K	Hold	2,000	–	–	﹤0.01%	680
2019 Q1	$9K	Hold	2,000	–	–	﹤0.01%	653
2018 Q4	$6K	Hold	2,000	–	–	﹤0.01%	630
2018 Q3	$15K	Hold	2,000	–	–	﹤0.01%	677
2018 Q2	$9K	Hold	2,000	–	–	﹤0.01%	690
2018 Q1	$10.8K	Buy	+2,000	New	+$13.2K	﹤0.01%	685

Other funds holding PLX

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Davenport & Co's PLX Position: Q4 2022 in Review

Davenport & Co sold out of Protalix BioTherapeutics (PLX) in Q4 2022, closing a stake of 22,000 shares — an estimated $23K sold.

Davenport & Co first reported a position in PLX in Q1 2018 and held it in 14 quarters. The position peaked at $54K in Q1 2021. 26 funds tracked by Wall St. Rank hold PLX as of Q4 2022.

Davenport & Co reported no remaining Protalix BioTherapeutics position as of Q4 2022 after selling out during the quarter.
Davenport & Co sold 22,000 Protalix BioTherapeutics shares in Q4 2022, an estimated $23K.
Davenport & Co first reported a position in Protalix BioTherapeutics in Q1 2018 and held it in 14 quarters.
Davenport & Co's Protalix BioTherapeutics position peaked at $54K in Q1 2021.
26 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2022.

Based on Davenport & Co's 13F filing for Q4 2022, filed 20 Jan 2023.